Provided by Tiger Trade Technology Pte. Ltd.

Longeveron Inc

6.90
+0.18002.68%
Post-market: 6.900.00000.00%16:10 EDT
Volume:104.62K
Turnover:729.67K
Market Cap:21.80M
PE:-0.69
High:7.30
Open:6.75
Low:6.51
Close:6.72
52wk High:12.30
52wk Low:4.75
Shares:3.16M
Float Shares:2.73M
Volume Ratio:0.99
T/O Rate:3.84%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-10.0000
EPS(LYR):-12.9172
ROE:-203.61%
ROA:-90.95%
PB:2.10
PE(LYR):-0.53

Loading ...

Longeveron Announces Independent Data Monitoring Committee Positive Review and Recommendation to Complete Phase 2B Stem Cell Therapy Clinical Trial in Hypoplastic Left Heart Syndrome (Hlhs)

THOMSON REUTERS
·
May 11

Longeveron Inc - Top-Line Results From Elpis Ii Trial Anticipated in August 2026

THOMSON REUTERS
·
May 11

Longeveron Inc - DMC Finds No Safety Concerns, Recommends Phase 2B Trial Continue to Completion

THOMSON REUTERS
·
May 11

Longeveron provides update on laromestrocel development after Type C meeting

TIPRANKS
·
May 09

Longeveron Updates FDA Path for ELPIS II Trial

TIPRANKS
·
May 09

Longeveron Says the FDA No Longer Sees Trial for Heart Syndrome Treatment as Pivotal

Dow Jones
·
May 09

Longeveron targets August ELPIS II Phase 2b HLHS data readout for laromestrocel

Reuters
·
May 09

Longeveron Inc - FDA Says New Primary Endpoint for Elpis Ii Cannot Be Agreed While Trial Ongoing

THOMSON REUTERS
·
May 09

Longeveron Announces Constructive Type C Meeting With U.S. FDA Ahead of Data Readout for Elpis Ii Phase 2B Clinical Trial Evaluating Treatment for Hypoplastic Left Heart Syndrome (Hlhs)

THOMSON REUTERS
·
May 09

Longeveron to Report 2026 First Quarter Financial Results and Host Conference Call on May 13, 2026

GlobeNewswire
·
May 06

Longeveron Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
May 04

Longeveron price target lowered to $8 from $10 at H.C. Wainwright

TIPRANKS
·
May 04

Analysts Are Bullish on These Healthcare Stocks: ARS Pharmaceuticals (SPRY), Longeveron (LGVN)

TIPRANKS
·
Apr 15

Longeveron Restores Executive Pay After Recent Financing

TIPRANKS
·
Apr 11

BRIEF-Longeveron Inc - Repaid Executives For Compensation Reductions Following Financing - SEC Filing

Reuters
·
Apr 11

Longeveron Inc - Board Approves 250,000 Rsu Grant to Executives, 500,000 Rsus to CEO - SEC Filing

THOMSON REUTERS
·
Apr 11

Longeveron grants CEO 500,000 RSUs, executives 250,000 after financing closes

Reuters
·
Apr 11

BRIEF-Longeveron Prospectus Filed For Resale Of Up To 30.9 Million Class A Common Shares By Selling Stockholders- SEC Filing

Reuters
·
Apr 11

Longeveron granted Chinese patent for potency assay methods

TIPRANKS
·
Apr 08

BUZZ-Longeveron rises as it wins China patent for stem cell test

Reuters
·
Apr 08